WGS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

120.49M

+25.98%

0.107

-83.14%

117.79M

+35.21%

-0.005

-101.83%

128.18M

+24.81%

0.057

-88.67%

Estimates Revision

The market is revising No Change the revenue expectations for GeneDx Holdings Corp. (WGS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 23.29%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+23.29%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 155.24 USD with a low forecast of 118.42 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 150.460

Low

118.42

Averages

155.24

High

170.00

Current: 150.460

Low

118.42

Averages

155.24

High

170.00

Piper Sandler

David Westenberg

upgrade

$140 -> $160

2025-11-10

Reason

Piper Sandler

David Westenberg

Price Target

$140 -> $160

2025-11-10

upgrade

Reason

Piper Sandler analyst David Westenberg raised the firm's price target on GeneDx to $160 from $140 following quarterly results. The firm keeps an Overweight rating on the shares.

Guggenheim

Buy

upgrade

$115 -> $170

2025-10-29

Reason

Guggenheim

Price Target

$115 -> $170

2025-10-29

upgrade

Buy

Reason

Guggenheim raised the firm's price target on GeneDx to $170 from $115 and keeps a Buy rating on the shares following what the firm calls out as another quarter of whole exome and genome growth, strong average selling prices, and gross margin improvements. With "a large beat and even larger guidance raise," the firm does not believe management intended to signal a move to negative EPS despite management's comments on 2026 operating expenses, the analyst added.

Canaccord

Buy

maintain

$155 -> $160

2025-10-29

Reason

Canaccord

Price Target

$155 -> $160

2025-10-29

maintain

Buy

Reason

Canaccord raised the firm's price target on GeneDx to $160 from $155 and keeps a Buy rating on the shares. The firm said they remain bullish after another quarter of solid execution and continued profitable growth, driving increased long-term estimates. Canaccord noted GeneDx's strategy to convert existing customers to WES/WGS and ramp new indications is driving solid growth.

BTIG

Buy

maintain

$140 -> $165

2025-10-29

Reason

BTIG

Price Target

$140 -> $165

2025-10-29

maintain

Buy

Reason

BTIG raised the firm's price target on GeneDx to $165 from $140 and keeps a Buy rating on the shares. The company delivered another strong quarter, posting best-in-class 65% Y/Y growth in its core exome/genome revenue, resulting in an 11% top line beat and a beat to the bottom line, and the management raised its 2025 guidance, the analyst tells investors in a research note. In order to capitalize on penetrating at least one large new market opportunity - the pediatrician market - GeneDx has initiated a step-up in hiring/spending, the firm added.

Canaccord

initiated

$155

2025-10-20

Reason

Canaccord

Price Target

$155

2025-10-20

initiated

Reason

Canaccord initiated coverage of GeneDx with a Buy rating and $155 price target. The company has undergone a "significant" financial turnaround, driven by its shift to high-value exome and genome testing, the analyst tells investors in a research note. The firm says GeneDx's leading position in the "underpenetrated market" of newborn screening and its long-term opportunity in adult testing could support solid near- and long-term performance.

Piper Sandler

Overweight

maintain

$120 -> $140

2025-09-11

Reason

Piper Sandler

Price Target

$120 -> $140

2025-09-11

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on GeneDx to $140 from $120 and keeps an Overweight rating on the shares. The firm maintains a positive outlook on GeneDx, supported by its unique data asset, demonstrated execution, and compelling growth prospects. Piper thinks the company's ability to build markets within the evolving rare disease testing landscape, coupled with its strategic expansion into high-potential areas like the NICU and general pediatrics, creates a compelling multi-year growth story. While the firm is mindful of the execution risks involved in scaling new markets and integrating acquisitions, Piper believes GeneDx's leadership, differentiated data moat, and proactive strategy position it well. The stock has had a nice run, but the firm still likes the stock and recommends buying more on a pullback.

Valuation Metrics

The current forward P/E ratio for GeneDx Holdings Corp (WGS.O) is 501.06, compared to its 5-year average forward P/E of 26.39. For a more detailed relative valuation and DCF analysis to assess GeneDx Holdings Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

26.39

Current PE

501.06

Overvalued PE

126.12

Undervalued PE

-73.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-36.53

Current EV/EBITDA

2551.42

Overvalued EV/EBITDA

524.17

Undervalued EV/EBITDA

-597.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.29

Current PS

8.67

Overvalued PS

56.87

Undervalued PS

-22.29

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1652.99% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1652.99% over the last month.

Sold

Bought

WGS News & Events

Events Timeline

No data

News

3.0

12-11MarketWatch

Eight Stock Selections to Capitalize on a Robust Sector of the Market

4.5

12-07Benzinga

The Inside Scoop:

7.0

11-30PRnewswire

GeneDx Holdings Under Investigation for Potential Shareholder Rights Breach

People Also Watch

Frequently Asked Questions

What is GeneDx Holdings Corp (WGS) stock price today?

The current price of WGS is 150.46 USD — it has decreased -0.69 % in the last trading day.

What is GeneDx Holdings Corp (WGS)'s business?

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

What is the price predicton of WGS Stock?

What is GeneDx Holdings Corp (WGS)'s revenue for the last quarter?

GeneDx Holdings Corp revenue for the last quarter amounts to 116.74M USD, increased 51.86 % YoY.

What is GeneDx Holdings Corp (WGS)'s earnings per share (EPS) for the last quarter?

GeneDx Holdings Corp. EPS for the last quarter amounts to -0.27 USD, decreased -12.90 % YoY.

What changes have occurred in the market's expectations for GeneDx Holdings Corp (WGS)'s fundamentals?

How many employees does GeneDx Holdings Corp (WGS). have?

GeneDx Holdings Corp (WGS) has 1000 emplpoyees as of December 15 2025.

What is GeneDx Holdings Corp (WGS) market cap?

Today WGS has the market capitalization of 4.38B USD.